Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease - a possible side effect?

Current Drug Safety

Volumn 9, Issue 2, 2014, Pages 156-158

  Georgalas, Ilias ^a   Papaconstantinou, Dimitris ^a   Papadopoulos, Kostas ^a   Pagoulatos, Dionisis ^a   Karagiannis, Dimitris ^b   Koutsandrea, Chryssanthi ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Ophthalmiatreio Athens Eye Hospital   (Greece)

Author keywords

Diabetic retinopathy; Intravitreal anti vascular endothelial growth factor; Renal damage

Indexed keywords

BEVACIZUMAB; CREATININE; HEMOGLOBIN A1C; PIG INSULIN; RANIBIZUMAB; UREA; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; B SCAN; BLURRED VISION; BODY WEIGHT; CASE REPORT; CHRONIC KIDNEY DISEASE; CONSULTATION; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; EYE SURGERY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMATURIA; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY INJURY; LASER COAGULATION; MALE; MIDDLE AGED; NEPHROLOGIST; OPHTHALMOSCOPY; PANRETINAL PHOTOCOAGULATION; PATIENT MONITORING; PERCEPTION; PRIORITY JOURNAL; PROTEINURIA; RETINA DETACHMENT; TRACTIONAL RETINAL DETACHMENT; UREA BLOOD LEVEL; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; KIDNEY;

AGED; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904750552     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886309666140211113635     Document Type: Article

References (14)

1. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2(11): 667-73.
2. Titchenell PM, Antonetti DA. Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy. Diabetes 2013; 62(6): 1808-15.
3. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248(6): 785-91.
4. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol 2012; 96(2): 167-78.
5. Davidović SP, Nikolić SV, Curić NJ, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy Eur J Ophthalmol 2012; 22(5): 792-8.
6. den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen. Kidney injury during VEGF inhibitor therapy. CMNethJ Med 2012; 70(6): 267-71.
7. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. EurJ Cancer 2010; 46(2): 439-48.
8. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. AmJ Kidney Dis 2007; 50(2): 203-18.
9. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114(10): 1860-7.
10. Pellé G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. AmJ Kidney Dis 2011; 57(5): 756-9.
11. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114(12): 2179-82.
12. Karagiannis DA, Ladas ID, Parikakis E, et al. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? Clin Interv Aging 2009; 4: 457-61.
13. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007; 27(9): 1260-6.
14. Jamrozy-Witkowska A, Kowalska K, Jankowska-Lech I, TerelakBorys B, Nowosielska A, Grabska-Liberek I. Complications of intravitreal injections--own experience. Klin Oczna 2011; 113(4-6): 127-31.